A Memorial Sloan Kettering Cancer Center VP is giving the institute $1.4 million he made from representing it on a biotech board, the New York Times and ProPublica report.
Researchers find that fecal microbiome transplants restore gut bacteria in cancer patients who underwent antibiotic treatment for a stem cell transplant.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Memorial Sloan Kettering Cancer Center's José Baselga has resigned following revelations he did not properly disclose industry ties in research articles.
The tool, called Cerebro, significantly outperformed other publicly available methods, including in the less-trafficked areas of the genome that are now relevant for TMB immunotherapy prediction.
The New York Times reports that José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, didn't always disclose industry ties.
MSKCC investigators showed that truncated mRNAs can inactivate tumor suppressor genes, fueling cancer development even without the presence of DNA mutations.
In a pair of commentaries, researchers critique last year's paper reporting the use of CRISPR/Cas9 to correct a mutation in viable human embryos.
Stat News reports that IBM's Watson supercomputer sometimes gives inappropriate cancer treatment advice.
In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.